Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma

A. Woodcock, E.R. Bleecker, J. Lötvall, P.M. O‘Byrne, E.D. Bateman, H. Medley, A. Ellsworth, L. Jacques, W.W. Busse (Manchester, Uxbridge, Madison, United Kingdom; Winston-Salem, Research Triangle Park, United States Of America; Gothenburg, Sweden; Hamilton, Canada; Cape Town, South Africa)

Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Session: Trials in asthma: asthma exacerbations and severe asthma
Session type: Poster Discussion
Number: 1795
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Woodcock, E.R. Bleecker, J. Lötvall, P.M. O‘Byrne, E.D. Bateman, H. Medley, A. Ellsworth, L. Jacques, W.W. Busse (Manchester, Uxbridge, Madison, United Kingdom; Winston-Salem, Research Triangle Park, United States Of America; Gothenburg, Sweden; Hamilton, Canada; Cape Town, South Africa). Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma. Eur Respir J 2012; 40: Suppl. 56, 1795

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Seasonality of asthma exacerbations: efficacy of fluticasone furoate/vilanterol 100/25µg (FF/VI) vs fluticasone furoate 100µg (FF) alone
Source: International Congress 2017 – Asthma management
Year: 2017


Fluticasone propionate/formoterol fumarate (FLUT/FORM) combination therapy has comparable efficacy to fluticasone propionate/salmeterol xinafoate (FLUT/SAL) in paediatric patients with asthma
Source: Annual Congress 2011 - Treating childhood asthma
Year: 2011


A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD
Source: Eur Respir J 2014; 43: 763-772
Year: 2014



Efficacy and safety of ciclesonide compared with fluticasone propionate or budesonide in adolescent patients with persistent asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 458s
Year: 2007

Efficacy and safety of the new beclomethasone dipropionate/formoterol combination vs. fluticasone propionate/salmeterol pMDIs in moderate to severe persistent asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 205s
Year: 2006

Safety and efficacy of fluticasone furoate/vilanterol trifenatate (FFVI) in COPD patients
Source: Annual Congress 2010 - Bronchodilators in airways disease
Year: 2010

Clinical efficacy of once-daily mometasone furoate in children with persistent asthma switched from treatment with fluticasone propionate
Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Year: 2011

Effectiveness and safety of fluticasone propionate/salmeterol 250/50mcg administered once daily to patients with persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 309s
Year: 2004

Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012

Efficacy of combination fluticasone furoate/vilanterol (FF/VI) and salmeterol/fluticasone propionate (SFC) over 12 weeks in patients with COPD
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012

Efficacy of the novel inhaled corticosteroid, fluticasone furoate (FF)/long-acting beta2-agonist, vilanterol (VI) combination in reducing COPD exacerbations
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012

Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma
Source: Eur Respir J 2014; 43: 773-782
Year: 2014



Efficacy and safety of fluticasone propionate/salmeterol DISKUS and fluticasone propionate DISKUS and HFA in children
Source: Eur Respir J 2005; 26: Suppl. 49, 161s
Year: 2005

Once-daily versus twice-daily administration of mometasone furoate dry powder inhaler (MF-DPI) improves lung function in children with asthma previously maintained on inhaled corticosteroids (ICS)
Source: Eur Respir J 2004; 24: Suppl. 48, 164s
Year: 2004

Initial maintenance therapy with fluticasone propionate/ salmeterol combination product provides superior asthma control versus montelukast or fluticasone propionate alone
Source: Eur Respir J 2002; 20: Suppl. 38, 386s
Year: 2002

Efficacy and safety of ciclesonide compared with fluticasone propionate in patients with moderate to severe asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 206s
Year: 2006

Safety profile of ciclesonide as compared with fluticasone propionate in the treatment of children and adolescents with asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 346s
Year: 2004

Efficacy and safety of fluticasone/formoterol compared to fluticasone alone in patients with asthma
Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD
Year: 2012

²Stepping down[/quot] from fluticasone propionate/salmeterol 100/50mcg Diskus® results in loss of asthma control
Source: Eur Respir J 2004; 24: Suppl. 48, 309s
Year: 2004

Treatment effectiveness and exacerbations during one year with seretide compared to fluticasone propionate and salmeterol in mild-to-moderate asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 176s
Year: 2001